CURI vs LOB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

CURI

35.2
AI Score
VS
LOB Wins

LOB

44.5
AI Score

Investment Advisor Scores

CURI

35score
Recommendation
SELL

LOB

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CURI LOB Winner
Net Income -6.43M 93.19M LOB
ROE -15.5% 7.1% LOB
ROA -8.5% 0.5% LOB
Total Assets 75.73M 16.97B LOB
Free Cash Flow 12.96M 238.11M LOB

Relative Price Performance (Last 90 Days)

CURI 1M: -13.9% · 3M: -13.9% LOB 1M: -1.1% · 3M: -19.6%

Current Technical Phase

CURI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 35

RSI (14): 35.2 · Price: $2.41

LOB

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.1%), weak momentum, RSI 43

RSI (14): 43.1 · Price: $34.40

Fundamentals Snapshot

Metric CURI LOB
Market Cap — —
Forward P/E 7.8 8.3
Trailing P/E — 12.3
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.6% 1.0%
Operating Margin 0.4% 0.3%
EPS 0.00 2.81
Dividend Yield 0.13% 0.00%

Frequently Asked Questions

Based on our detailed analysis, LOB is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.